Valuation: Haleon plc

Market Cap 30.19B 39.97B 35.07B 33.13B 56.51B 3,831B 56.91B 396B 154B 1,957B 150B 147B 6,290B P/E 2026 *
17.8x
P/E 2027 * 15.8x
Enterprise Value 37.09B 49.11B 43.09B 40.7B 69.43B 4,707B 69.93B 487B 189B 2,405B 184B 180B 7,728B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 3.08x
Free-Float
98.46%
Yield 2026 *
2.36%
Yield 2027 * 2.61%

Last Transcript: Haleon plc

1 day+0.43%
1 week-0.22%
Current month-7.68%
1 month-8.95%
3 months+0.22%
6 months-5.03%
Current year-8.41%
1 week 9.11
Extreme 9.11
9.39
1 month 9.1
Extreme 9.1
10.2
Current year 8.65
Extreme 8.65
11.28
1 year 8.65
Extreme 8.65
11.28
3 years 7.7
Extreme 7.695
11.42
5 years 5.59
Extreme 5.59
11.42
10 years 5.59
Extreme 5.59
11.42
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%-0.22% - - 39.97B
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.45%+0.74%+30.13%+48.47% 404.26B
Weighted average by Cap. +0.27%+1.32%+40.43%+68.21%

Financials

2026 *2027 *
Net sales 11.38B 15.07B 13.23B 12.49B 21.31B 1,445B 21.46B 149B 57.9B 738B 56.6B 55.37B 2,372B 11.87B 15.71B 13.79B 13.02B 22.21B 1,506B 22.37B 156B 60.35B 769B 58.99B 57.72B 2,473B
Net income 1.7B 2.25B 1.97B 1.86B 3.18B 215B 3.2B 22.29B 8.63B 110B 8.44B 8.26B 354B 1.91B 2.53B 2.22B 2.1B 3.58B 243B 3.61B 25.12B 9.73B 124B 9.51B 9.31B 399B
Net Debt 6.9B 9.14B 8.02B 7.57B 12.92B 876B 13.01B 90.63B 35.1B 447B 34.31B 33.57B 1,438B 6.3B 8.34B 7.32B 6.91B 11.8B 800B 11.88B 82.75B 32.05B 409B 31.33B 30.65B 1,313B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-09-25 US$9.260 +0.43% 22,366,229
26-09-24 US$9.220 +1.21% 16,840,624
26-09-23 US$9.110 -1.51% 21,338,640
26-09-22 US$9.250 -1.18% 29,491,418
26-09-21 US$9.360 +0.86% 40,721,397
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.427GBP
Average target price
4.196GBP
Spread / Average Target
+22.45%

Quarterly revenue - Rate of surprise